{
  "symbol": "PAVM",
  "company_name": "Pavmed Inc",
  "ir_website": "https://www.pavmed.com/investor-relations/",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Press Release Example 2024",
          "url": "https://ir.pavmed.com/press-releases/2024-01-15-press-release-example",
          "content": "Investor Relations\n\n## Press Releases\n\nMonth Year \n\nSu  |  Mo  |  Tu  |  We  |  Th  |  Fr  |  Sa   \n---|---|---|---|---|---|---  \n25  |  26  |  27  |  28  |  29  |  30  |  1   \n2  |  3  |  4  |  5  |  6  |  7  |  8   \n9  |  10  |  11  |  12  |  13  |  14  |  15   \n16  |  17  |  18  |  19  |  20  |  21  |  22   \n23  |  24  |  25  |  26  |  27  |  28  |  29   \n30  |  31  |  1  |  2  |  3  |  4  |  5   \n  \nCancel  Go\n\nMonth Year \n\nSu  |  Mo  |  Tu  |  We  |  Th  |  Fr  |  Sa   \n---|---|---|---|---|---|---  \n25  |  26  |  27  |  28  |  29  |  30  |  1   \n2  |  3  |  4  |  5  |  6  |  7  |  8   \n9  |  10  |  11  |  12  |  13  |  14  |  15   \n16  |  17  |  18  |  19  |  20  |  21  |  22   \n23  |  24  |  25  |  26  |  27  |  28  |  29   \n30  |  31  |  1  |  2  |  3  |  4  |  5   \n  \nCancel  Go\n\n[ Email Alerts![](images/webdriver/email_alerts.png) ](https://ir.pavmed.com/email-alerts?type=1)\n\nYear All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 Keywords Go\n\n[Advanced Search](#)\n\nSearch\n\nSearch Headlines Only\n\nFrom\n\nTo\n\nAsset Types\n\nPhotos Video Audio Documents Events Standard\n\n[Basic Search](#)\n\n  * Nov 20, 2024\n\n[Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test](https://ir.pavmed.com/2024-11-20-Lucid-Diagnostics-Submits-Clinical-Evidence-Package-to-MolDX-Seeking-Medicare-Coverage-for-EsoGuard-R-Esophageal-DNA-Test)\n\nLucid Diagnostics Inc. (Nasdaq: LUCD) (\"Lucid\" or the \"Company\") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced...\n\n  * Nov 18, 2024\n\n[Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum](https://ir.pavmed.com/2024-11-18-Lucid-Diagnostics-to-Present-at-the-Canaccord-Genuity-MedTech,-Diagnostics-and-Digital-Health-Services-Forum)\n\nLucid Diagnostics Inc. (Nasdaq: LUCD) (\"Lucid\" or the \"Company\"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced...\n\n  * Nov 14, 2024\n\n[PAVmed Provides Business Update and Third Quarter 2024 Financial Results](https://ir.pavmed.com/2024-11-14-PAVmed-Provides-Business-Update-and-Third-Quarter-2024-Financial-Results)\n\nLucid reports record quarterly EsoGuard® revenue and completes clinical evidence package for imminent submission to formally seek Medicare coverage Veris Health completes pilot program with The...\n\n  * Nov 13, 2024\n\n[Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results](https://ir.pavmed.com/2024-11-13-Lucid-Diagnostics-Provides-Business-Update-and-Third-Quarter-2024-Financial-Results)\n\nEsoGuard® revenue up 20 percent sequentially Clinical evidence package for Medicare coverage submission complete Direct contracting initiative expanded to multiple programs to drive near-term...\n\n  * Nov 7, 2024\n\n[Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication](https://ir.pavmed.com/2024-11-07-Lucid-Diagnostics-ESOGUARD-BE-1-Prospective-Multicenter-Clinical-Validation-Study-of-EsoGuard-R-Esophageal-Precancer-Testing-Accepted-for-Peer-Reviewed-Publication)\n\nPublication, which once again demonstrates strong EsoGuard performance in a screening population, completes Lucid's clinical evidence package for submission to formally seek Medicare coverage NEW YORK\n\n\n\n\nShow \n\n5\n\nper page\n\n  * [](#print \"print\")\n  * [ ](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fir.pavmed.com%2Findex.php%3Fs%3D43 \"Facebook Share\")\n  * [ ](https://www.linkedin.com/shareArticle?mini=true&url=https%3A%2F%2Fir.pavmed.com%2Findex.php%3Fs%3D43 \"Linkedin Share\")\n  * [ ](https://twitter.com/share?url=https%3A%2F%2Fir.pavmed.com%2Findex.php%3Fs%3D43 \"Twitter Share\")\n  * [](#email \"email\")\n  * [](https://ir.pavmed.com/rss?rsspage=43 \"rss\")\n\n\n\n[5](https://ir.pavmed.com/press-releases?l=5)[10](https://ir.pavmed.com/press-releases?l=10)[25](https://ir.pavmed.com/press-releases?l=25)[50](https://ir.pavmed.com/press-releases?l=50)[100](https://ir.pavmed.com/press-releases?l=100)\n"
        },
        {
          "title": "New Product Announcement 2024",
          "url": "https://ir.pavmed.com/press-releases/2024-02-01-new-product-announcement",
          "content": "Investor Relations\n\n## Press Releases\n\nMonth Year \n\nSu  |  Mo  |  Tu  |  We  |  Th  |  Fr  |  Sa   \n---|---|---|---|---|---|---  \n25  |  26  |  27  |  28  |  29  |  30  |  1   \n2  |  3  |  4  |  5  |  6  |  7  |  8   \n9  |  10  |  11  |  12  |  13  |  14  |  15   \n16  |  17  |  18  |  19  |  20  |  21  |  22   \n23  |  24  |  25  |  26  |  27  |  28  |  29   \n30  |  31  |  1  |  2  |  3  |  4  |  5   \n  \nCancel  Go\n\nMonth Year \n\nSu  |  Mo  |  Tu  |  We  |  Th  |  Fr  |  Sa   \n---|---|---|---|---|---|---  \n25  |  26  |  27  |  28  |  29  |  30  |  1   \n2  |  3  |  4  |  5  |  6  |  7  |  8   \n9  |  10  |  11  |  12  |  13  |  14  |  15   \n16  |  17  |  18  |  19  |  20  |  21  |  22   \n23  |  24  |  25  |  26  |  27  |  28  |  29   \n30  |  31  |  1  |  2  |  3  |  4  |  5   \n  \nCancel  Go\n\n[ Email Alerts![](images/webdriver/email_alerts.png) ](https://ir.pavmed.com/email-alerts?type=1)\n\nYear All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 Keywords Go\n\n[Advanced Search](#)\n\nSearch\n\nSearch Headlines Only\n\nFrom\n\nTo\n\nAsset Types\n\nPhotos Video Audio Documents Events Standard\n\n[Basic Search](#)\n\n  * Nov 20, 2024\n\n[Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test](https://ir.pavmed.com/2024-11-20-Lucid-Diagnostics-Submits-Clinical-Evidence-Package-to-MolDX-Seeking-Medicare-Coverage-for-EsoGuard-R-Esophageal-DNA-Test)\n\nLucid Diagnostics Inc. (Nasdaq: LUCD) (\"Lucid\" or the \"Company\") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced...\n\n  * Nov 18, 2024\n\n[Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum](https://ir.pavmed.com/2024-11-18-Lucid-Diagnostics-to-Present-at-the-Canaccord-Genuity-MedTech,-Diagnostics-and-Digital-Health-Services-Forum)\n\nLucid Diagnostics Inc. (Nasdaq: LUCD) (\"Lucid\" or the \"Company\"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced...\n\n  * Nov 14, 2024\n\n[PAVmed Provides Business Update and Third Quarter 2024 Financial Results](https://ir.pavmed.com/2024-11-14-PAVmed-Provides-Business-Update-and-Third-Quarter-2024-Financial-Results)\n\nLucid reports record quarterly EsoGuard® revenue and completes clinical evidence package for imminent submission to formally seek Medicare coverage Veris Health completes pilot program with The...\n\n  * Nov 13, 2024\n\n[Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results](https://ir.pavmed.com/2024-11-13-Lucid-Diagnostics-Provides-Business-Update-and-Third-Quarter-2024-Financial-Results)\n\nEsoGuard® revenue up 20 percent sequentially Clinical evidence package for Medicare coverage submission complete Direct contracting initiative expanded to multiple programs to drive near-term...\n\n  * Nov 7, 2024\n\n[Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication](https://ir.pavmed.com/2024-11-07-Lucid-Diagnostics-ESOGUARD-BE-1-Prospective-Multicenter-Clinical-Validation-Study-of-EsoGuard-R-Esophageal-Precancer-Testing-Accepted-for-Peer-Reviewed-Publication)\n\nPublication, which once again demonstrates strong EsoGuard performance in a screening population, completes Lucid's clinical evidence package for submission to formally seek Medicare coverage NEW YORK\n\n\n\n\nShow \n\n5\n\nper page\n\n  * [](#print \"print\")\n  * [ ](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fir.pavmed.com%2Findex.php%3Fs%3D43 \"Facebook Share\")\n  * [ ](https://www.linkedin.com/shareArticle?mini=true&url=https%3A%2F%2Fir.pavmed.com%2Findex.php%3Fs%3D43 \"Linkedin Share\")\n  * [ ](https://twitter.com/share?url=https%3A%2F%2Fir.pavmed.com%2Findex.php%3Fs%3D43 \"Twitter Share\")\n  * [](#email \"email\")\n  * [](https://ir.pavmed.com/rss?rsspage=43 \"rss\")\n\n\n\n[5](https://ir.pavmed.com/press-releases?l=5)[10](https://ir.pavmed.com/press-releases?l=10)[25](https://ir.pavmed.com/press-releases?l=25)[50](https://ir.pavmed.com/press-releases?l=50)[100](https://ir.pavmed.com/press-releases?l=100)\n"
        }
      ]
    }
  ]
}